Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
about
Posttransplant lymphoproliferative disorders following liver transplantation: Where are we now?Burden of de novo malignancy in the liver transplant recipientPosttransplant lymphoproliferative disease after pediatric solid organ transplantationEpstein-Barr virus infection and posttransplant lymphoproliferative disorderRituximab in renal transplantationTowards gene therapy for EBV-associated posttransplant lymphoma with genetically modified EBV-specific cytotoxic T cells.Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report.Clinical review: Serious adverse events associated with the use of rituximab - a critical care perspective.Posttransplant lymphoproliferative disease after lung transplantation.Paraneoplastic pyoderma gangrenosum with posttransplant lymphoproliferative disorder.Rituximab-based treatments followed by adoptive cellular immunotherapy for biopsy-proven EBV-associated post-transplant lymphoproliferative disease in recipients of allogeneic hematopoietic stem cell transplantation.Chemoimmunotherapy and withdrawal of immunosuppression for monomorphic posttransplant lymphoproliferative disorders.Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation.Treatment of post-transplantation lymphoproliferative disorders after kidney transplant with rituximab and conversion to m-TOR inhibitor.Fcγ-receptor IIIA polymorphism p.158F has no negative predictive impact on rituximab therapy with and without sequential chemotherapy in CD20-positive posttransplant lymphoproliferative disorder.Practical guidelines: lung transplantation in patients with cystic fibrosis.Posttransplantation lymphoproliferative disorder after pediatric solid organ transplantation: experiences of 20 years in a single center.Managing post-transplant lymphoproliferative disorders in solid-organ transplant recipients: a review of immunosuppressant regimens.Indications for use and safety of rituximab in childhood renal diseases.Viral infections and their management in patients with chronic lymphocytic leukemia.Lymphoproliferative disorders in immunocompromised individuals and therapeutic antibodies for treatment.Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies.Infectious complications of immune modulatory agents.Post-transplant lymphoproliferative disorder presenting as a tumor adjacent to the renal allograft: A case report and review of the literature.Managing the challenge of PTLD in liver and bowel transplant recipients.Primary central nervous system posttransplantation lymphoproliferative disorder after heart and lung transplantation.II. Challenges in the management of post-transplant lymphoproliferative disorder.Posttransplant Lymphoproliferative Disorder: Otolaryngological Manifestations and Management.Childhood, adolescent and young adult non-Hodgkin lymphoma: state of the science.Epstein-Barr Virus-Positive Posttransplant Lymphoproliferative Disease After Solid Organ Transplantation: Pathogenesis, Clinical Manifestations, Diagnosis, and Management.A comprehensive analysis of the cellular and EBV-specific microRNAome in primary CNS PTLD identifies different patterns among EBV-associated tumors.Survival Analyses and Prognosis of Plasma-Cell Myeloma and Plasmacytoma-Like Posttransplantation Lymphoproliferative Disorders.Pretransplant prophylactic rituximab to prevent Epstein-Barr virus (EBV) viremia in EBV-seronegative kidney transplant recipients from EBV-seropositive donors: results of a pilot study.A 47-year-old stem cell transplant recipient with fever, cough and chest pain.Post-transplant lymphoproliferative disorder presenting with skin ulceration in a renal transplant recipient who achieved sustained remission with rituximab therapy: A case report.A Solid Mass in the Chest Wall.First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study.Hodgkin lymphoma post-transplant lymphoproliferative disorder: A comparative analysis of clinical characteristics, prognosis, and survival.The Impact of EBV Status on Characteristics and Outcomes of Posttransplantation Lymphoproliferative Disorder.Primary Central Nervous System Posttransplant Lymphoproliferative Disease in a Bilateral Transfemoral Lower Extremity Transplantation Recipient.
P2860
Q26780262-36E35808-C715-4C48-BA08-18889A9554D4Q26859216-BEA8B7E0-DE7A-4910-8A52-D20CD6C5F7D8Q26866013-571EE91C-71E3-43FF-A4E3-4A977C175DD7Q27024229-A9139CFD-9BCB-4402-9886-3A8F73D95B8CQ27026434-30F77DF2-97D5-42BD-B36B-726482B594ECQ34353696-BBE5B90B-64A4-462E-9DA0-BD21CE37698EQ36356785-9FF534E3-8F34-458A-AFD3-AFBB185C7BE6Q36633769-EED3D62A-028E-4016-AD52-3BFD5A8D1DD4Q36701511-639DB861-4A7B-40A3-8A42-FB20A39819A6Q36798703-BAC4A739-8850-400E-A8EB-F5D83EE69E4CQ37012569-FB44961D-ABA3-435C-B9B0-201087363FC0Q37355856-EAEDF1CD-B4FC-4E2F-924D-68AE36926915Q37426542-CD9B1A75-1A1F-4BAB-9C19-41C51FC4103DQ37679263-A904167D-C285-494B-9EB7-C6A2712BD3E6Q37704588-350EB273-0648-446C-AF73-3FED6B74B4F6Q37706330-0A336C4C-E79C-4825-8D6E-7C9C0082C071Q37740522-75E0A54C-A055-4F84-997C-3D52B71F7757Q38032320-5CC46645-7FCA-4A07-9503-656BD8312211Q38044851-D5EFCA94-DB70-4992-932A-C2CEFCEF574DQ38064527-5CE0A8F4-9C49-48AC-90A5-C01CCB9E8600Q38096060-F5EF4E8D-D9B6-4E19-B475-ED507245D4E9Q38112050-5449AC6E-5545-46F8-969C-E224B2DC3938Q38144976-4EC163D5-D7A2-4C02-B51F-32B3F140F578Q38264424-89BC3958-C61C-420E-97A3-CA4C58F391A8Q38265869-F16FE831-0577-441C-9C9B-FC29A9EA4D66Q38467463-39EAB261-4BB8-47BE-8E53-F36ED1990540Q38524036-7B5307DD-10A4-4530-AEA3-4D797E76729DQ38680172-D18D1D13-A2A3-4517-A3BF-609A5E345448Q38822525-1214FF59-AC27-471D-AC94-AEBA9338B9C6Q38833567-6A55304D-6BB7-42CF-B2B2-4D8068E3A928Q38965273-46B2E97E-BC24-4F4C-8091-6B353C590523Q39258590-80A51598-1002-4D5B-841B-39EB17EF94BEQ39386528-CFAE6D00-1C4D-4B10-BE62-0D4B9BAFDEC5Q40152435-7D9A0A2E-2A37-4F5E-AB36-F3EA1DBD5886Q40430658-CD1E3518-C640-465B-8AD1-A37A4B1CB1E6Q40609933-6282B7F3-DB7C-4882-B799-F99E6322A76CQ40656850-4C12EB1B-3576-4F13-A611-4B98A6C95F8FQ40879703-25EAD4A6-AEB9-4500-AB6E-C0A67E950F7AQ41219311-FB193917-1F73-4E1A-8E70-8CEF53120A15Q41235998-46725C0B-7442-4AEB-B2F4-C90EA07AF863
P2860
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Sequential treatment with ritu ...... ticentre phase 2 PTLD-1 trial.
@en
Sequential treatment with ritu ...... t lymphoproliferative disorder
@nl
type
label
Sequential treatment with ritu ...... ticentre phase 2 PTLD-1 trial.
@en
Sequential treatment with ritu ...... t lymphoproliferative disorder
@nl
prefLabel
Sequential treatment with ritu ...... ticentre phase 2 PTLD-1 trial.
@en
Sequential treatment with ritu ...... t lymphoproliferative disorder
@nl
P2093
P50
P921
P1433
P1476
Sequential treatment with ritu ...... lticentre phase 2 PTLD-1 trial
@en
P2093
European PTLD Network
Franck Morschhauser
German PTLD Study Group
Hanno Riess
Hans Lehmkuhl
Heinz August Horst
Ioannis Anagnostopoulos
Malte Leithäuser
Martine Raphael
Monica Sender
P304
P356
10.1016/S1470-2045(11)70300-X
P577
2011-12-13T00:00:00Z